Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | AANAT | Q16613 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
| ▸ | IDE | P14735 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931472 | 0.89 | TRPV1 (0.52) | ALDH1A1MAPTCYP1A2BLM | |
| SCHEMBL7570987 | 0.85 | MEN1 (0.51) | MEN1KMT2AMTNR1AALDH1A1AANAT | |
| SCHEMBL931907 | 0.79 | MAPT (0.43) | MEN1KMT2AALDH1A1MAPTIDE | |
| SCHEMBL7394401 | 0.76 | MEN1 (0.55) | MEN1KMT2AMTNR1AALDH1A1AANAT | |
| SCHEMBL5332984 | 0.75 | TRPV1 (0.49) | ALDH1A1MAPTCYP1A2BLM | |
| SCHEMBL7677886 | 0.73 | MEN1 (0.84) | MEN1KMT2AMTNR1AALDH1A1AANAT | |
| SCHEMBL7684221 | 0.72 | HPRT1 (0.45) | KMT2ASMN1; SMN2 | |
| SCHEMBL7375871 | 0.71 | HPRT1 (0.58) | MEN1KMT2AMAPTTSHRL3MBTL1 | |
| SCHEMBL761481 | 0.71 | MTNR1A (0.88) | MEN1KMT2AMTNR1AALDH1A1AANAT | |
| SCHEMBL19051489 | 0.71 | MEN1 (0.80) | MEN1KMT2AMTNR1AALDH1A1AANAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6303617-B1 | FOR THERAPY OF OBESITY, LOWERING SERUM CHOLESTEROL AND HIGH DENSITY LIPOPROTEIN IN MAMMALS, INHIBITOR OF MONOAMINE OXIDASE | NEOTHERAPEUTICS, INC. | 2001-10-16 | — | — | US | claimed |
| WO-1999057120-A9 | NOVEL SEROTONIN-LIKE 9-SUBSTITUTED HYPOXANTHINE AND METHODS OF USE | NEOTHERAPEUTICS INC (US) | 2000-02-03 | — | — | WO | claimed |
| WO-1999057120-A1 | NOVEL SEROTONIN-LIKE 9-SUBSTITUTED HYPOXANTHINE AND METHODS OF USE | NEOTHERAPEUTICS, INC. (US) | 1999-11-11 | — | — | WO | claimed |
| EP-1334103-B1 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | SPECTRUM PHARMACEUTICALS INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-1790344-A2 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | Spectrum Pharmaceuticals, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-6630490-B2 | Purine derivative or analogue | NEOTHERAPEUTICS, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6630478-B2 | Administering to patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue | NEOTHERAPEUTICS, INC. | 2003-10-07 | — | — | US | disclosed |
| EP-1334103-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1334104-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | NEOTHERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2002058736-A2 | USE OF 9-SUBSTITUTED PURINE ANALOGUES AND OTHER MOLECULES TO STIMULATE NEUROGENESIS | NEOTHERAPETICS, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002004450-A2 | METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004452-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004451-A2 | METHODS FOR STIMULATION OF SYNTHESIS OF SYNAPTOPHYSIN IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| US-6303617-B1 | FOR THERAPY OF OBESITY, LOWERING SERUM CHOLESTEROL AND HIGH DENSITY LIPOPROTEIN IN MAMMALS, INHIBITOR OF MONOAMINE OXIDASE | NEOTHERAPEUTICS, INC. | 2001-10-16 | — | — | US | disclosed |
| WO-1999057120-A9 | NOVEL SEROTONIN-LIKE 9-SUBSTITUTED HYPOXANTHINE AND METHODS OF USE | NEOTHERAPEUTICS INC (US) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999057120-A9 | NOVEL SEROTONIN-LIKE 9-SUBSTITUTED HYPOXANTHINE AND METHODS OF USE | NEOTHERAPEUTICS INC (US) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999057120-A1 | NOVEL SEROTONIN-LIKE 9-SUBSTITUTED HYPOXANTHINE AND METHODS OF USE | NEOTHERAPEUTICS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999057120-A1 | NOVEL SEROTONIN-LIKE 9-SUBSTITUTED HYPOXANTHINE AND METHODS OF USE | NEOTHERAPEUTICS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | SLC29A1, ABCB1, NUDT1 | MEN1 4715/4885KMT2A 4036/4885MTNR1A 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.